India's Pfizer Ltd jumps as parent company says antiviral pill cuts risk of severe COVID-19 by 89%

Pfizer

08/11/2021 04:18

** Shares  PFIZ.NS  of the drugmaker's India arm up as much
as 7.1% at 5,363 rupees, biggest gain since July 27
    ** Parent Pfizer Inc  PFE.N  said on Friday its experimental
antiviral pill to treat COVID-19 cut by 89% the chance of
hospitalisation or death for adults at risk of severe disease
 urn:newsml:reuters.com:*:nL1N2RW0N5
    ** The trial's results suggest Pfizer's drug surpasses Merck
& Co Inc  MRK.N  pill, molnupiravir, which was shown to halve
the chance of dying or being hospitalised for COVID-19 patients
at high risk of serious illness
    ** PFE says it plans to submit interim trial results for the
pill called Paxlovid, to FDA before Nov. 25 and it could get
U.S. regulatory approval by year-end
    ** About 63,372 PFIZ shares change hands, 2x 30-day average
    ** PFIZ stock down 1.94% so far this year, as of last close

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com))